Novartis announced the latest progress of drug treatment of hepatitis B
March 27, at the twentieth annual meeting of the Asia-Pacific liver disease (APASL) for the first time opened in Beijing, the theme is "ExploringtheFrontiers, explore new areas." More than 5000 liver disease worldwide experts and scholars attended the event, chronic hepatitis B (hereinafter referred to as hepatitis B) in the treatment of new trends and strategies. During the meeting, Novartis liver disease experts to the media organization published the latest drug treatment of hepatitis B progress.
People's Liberation Army 302 Hospital, Professor Zhang Hongfei, director of liver image that the treatment of chronic hepatitis B not only suppress the virus, but also improve the immune function of patients to treatment in a limited time, so that patients with long-term conditions, steady improvement . Of the e antigen-positive patients, a sign of improved immune function is e antigen seroconversion. Therefore, the treatment should also strengthen the monitoring of e antigen.
"Limited period of time after treatment is antiviral therapy of science and ultimately helping patients to achieve drug withdrawal, but after stopping the virus remains inhibited by continuing condition was not repeated." Professor Zhang Hongfei pointed out that "if you select the correct treatment, received standard antiretroviral therapy, chronic hepatitis B patients completely without medication for life. "To ultimately stop, the recovery of immune function is a prerequisite. Professor Zhang Hongfei pointed out that, in order to achieve a limited course of treatment, antiviral drugs can inhibit not only virus, but also has immunomodulatory effects, "not only to evil, but also straight." Specific to the e antigen positive patients, in order to know whether treatment is effective, the need to find two targets, namely hepatitis B virus DNA and e antigen, the former reflects the hepatitis B virus replication is active, the virus is not detected in blood DNA showed that virus replication has been well inhibited; which is currently regarded by many clinicians, immune function, "vane", e antigen seroconversion (ie e antigen disappears, there e antibody) e antigen-positive patients is an important symbol to restore immunity. "Only the hepatitis B virus DNA was negative, then realized the e antigen seroconversion, our treatment can meet the more satisfactory results. The treatment goal, we figuratively called 'dual target', 'Double Standards' is to achieve limited treatment of the premise. "
This end, according to guide prevention and treatment of chronic hepatitis B should be chosen not only potent inhibition of virus e antigen can improve the conversion rate of drug. Clinical trials have shown that in HBV DNA suppression rate, the nucleotide (acid) analogue is superior to interferon, which the telbivudine and entecavir inhibition is higher. E antigen seroconversion in the area, the interferon is superior, while the nucleotide (acid) analogues only telbivudine conversion in the e antigen expression and interferon close. APASL2010 years to the latest clinical research data show telbivudine treatment for 4 years, patients with total e antigen seroconversion rate was 54%; while receiving telbivudine for 24 weeks of treatment in chronic hepatitis B virus DNA detected in patients 4-year cumulative e antigen seroconversion rate of up to 66%.
I am China Hardware Suppliers writer, reports some information about dynamo emergency radio , double cassette recorder.
Processing your request, Please wait....
